61eP Radiotherapy combined with PARP inhibition in BRCA-mutated breast cancer: A systematic review of clinical outcomes and toxicity

ESMO Open · Published 2026-07-01 · DOI 10.1016/j.esmoop.2026.107841

Free full text

Authors (1)

R.N. Modi

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Modi, R. (2026). 61eP Radiotherapy combined with PARP inhibition in BRCA-mutated breast cancer: A systematic review of clinical outcomes and toxicity. ESMO Open. https://doi.org/10.1016/j.esmoop.2026.107841

Related articles

• Nectin-4 and Trop-2 expression in collecting duct carcinoma: new promising therapeutic targets · ESMO Open · 2026 · Same journal
• 149P Adjuvant radiotherapy outcomes for early stage (stage 1c-2) clear cell ovarian carcinoma in Edinburgh cancer centre · ESMO Open · 2026 · Same journal
• 213P Glandular tissue–based versus anatomical landmark–based CTV delineation in postoperative breast cancer radiotherapy: A dosimetric comparison · ESMO Open · 2026 · Same journal
• 194eP Ovarian cancer during pregnancy: Maternal and fetal outcomes from a systematic review and meta-analysis · ESMO Open · 2026 · Same journal
• 67RO Single-cell and TCR profiling reveals pre-existing cytotoxic CD8 T cell clonal expansion and peripheral–tumor dissociation associated with response to PD-1-based therapy in hepatocellular carcinoma · ESMO Open · 2026 · Same journal
• 219P Clinical profile and treatment outcomes of lymphoma patients: A retrospective cohort study · ESMO Open · 2026 · Same journal
• A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma) · ESMO Open · 2026 · Same journal
• 152P Efficacy and safety of relacorilant + nab-paclitaxel in patients aged ≥65 years with platinum-resistant ovarian cancer (PROC) in the phase III ROSELLA study (GOG-3073, ENGOT-ov72, APGOT-Ov10) · ESMO Open · 2026 · Same journal
• 232eP GLP-1 receptor agonists and risk of incident endometrial, colorectal, and hepatocellular cancer: A systematic review and meta-analysis · ESMO Open · 2026 · Same journal
• 174eP Progesterone receptor expression and endocrine therapy outcomes in low-grade serous ovarian carcinoma · ESMO Open · 2026 · Same journal